I would like to thank Karen Domino, M.D., chair of the ASAs Committee on Practice Parameters (CPP) and Girish Joshi, M.D., vice-chair of the CPP, as well as ASAs Task Force on Preoperative Fasting for their commitment to patient safety in developing this guidance. Initial reports have found that patients who have experienced GI side effects, such as nausea or vomiting, while taking GLP-1 agonists were more likely to have increased residual gastric contents
It may also trigger adaptive metabolic responses that slow weight loss over time and increase the likelihood of weight regain after treatment cessation
Large meta-analyses have not identified an increased risk of acute pancreatitis versus placebo
The idea is simple: lose body fat and improve performance
Retatrutide and Semaglutide are two of the most actively researched incretin-based peptides in metabolic science
If your primary issue is a plateau on semaglutide, a permanent switch to tirzepatide is supported by stronger evidence than alternating